

Topic	Nirsevimab (Beyfortus™)	Clesrovimab (Enflonia™)
Manufacturer	AstraZeneca and Sanofi Prescribing Info (PDF) (FDA)	Merck Prescribing Info (PDF) (FDA)
Protects Against	Respiratory Syncytial Virus	Respiratory Syncytial Virus
Approved Ages	<ul style="list-style-type: none"> • Neonates & infants born during or entering their first RSV season • Children - 24 months who remain vulnerable to severe RSV disease through their second RSV season 	<ul style="list-style-type: none"> • Neonates & infants born during or entering their first RSV season
Funding Program	 California Vaccines for Children Program	 California Vaccines for Children Program
Routine Schedule & Intervals	<p>1 dose for all infants <8 months born during or entering their 1st RSV season if</p> <ul style="list-style-type: none"> • birth parent did not receive RSV vaccine during pregnancy • birth parent’s RSV vaccination status is unknown • infant was born within 14 days of prenatal RSV vaccination <p>Note: IHS guidance is for preferential use of nirsevimab over clesrovimab for American Indian/Alaska Native children (PDF).</p> <p>1 dose for children 8–19 months entering their 2nd RSV season & who are at increased risk for severe RSV:</p> <ul style="list-style-type: none"> • American Indian/Alaska Native children (PDF) • Children with chronic lung disease of prematurity who required medical support (chronic corticosteroids, diuretics, or supplemental oxygen) any time during the 6-month period before the start of the second RSV season • Children who are severely immunocompromised 	<p>1 dose for all infants <8 months born during or entering 1st RSV season if</p> <ul style="list-style-type: none"> • birth parent did not receive RSV vaccine during pregnancy • birth parent’s RSV vaccination status is unknown • infant was born within 14 days of prenatal RSV vaccination

Vaccine Fact Sheet: RSV

Topic	Nirsevimab (Beyfortus™)	Clesrovimab (Enflonsia™)
	<ul style="list-style-type: none"> Children with cystic fibrosis who have either: weight-for-length $\leq 10\%$ percentile or severe lung disease (previous hospitalization for pulmonary exacerbation in the first year of life or chest imaging abnormalities that persist when stable) 	-
Recommended Timing	<ul style="list-style-type: none"> For infants born during RSV season: Within 1 week of birth, ideally during the birth hospitalization; infants with prolonged birth hospitalizations should receive nirsevimab shortly before or promptly after hospital discharge For infants born outside of RSV season and children 8-19 months: Optimal administration is at start of RSV season, usually Oct Nirsevimab should be offered throughout the RSV season, typically Oct through Mar <p>See RSV Immunization Guide for Infants and Toddlers (PDF)</p>	<ul style="list-style-type: none"> For infants born during RSV season: Within 1 week of birth, ideally during the birth hospitalization; infants with prolonged birth hospitalizations should receive clesrovimab shortly before or promptly after hospital discharge For infants <8 months born outside the RSV season, administer once prior to the start of their first RSV season Clesrovimab should be offered throughout the RSV season, typically Oct-Mar <p>See RSV Immunization Guide for Infants and Toddlers (PDF)</p>
Administration	Intramuscular (IM) injection	Intramuscular (IM) injection
Packaging	<p>Pre-filled syringes:</p> <ul style="list-style-type: none"> 50mg (0.5mL) with purple plunger rod (for infants weighing <5 kg) 100 mg (1mL) with light blue plunger rod <p>Cartons of 5 pre-filled syringes:</p> <ul style="list-style-type: none"> Five 50 mg/0.5 mL single-dose pre-filled syringes in a carton Five 100 mg/1 mL single-dose pre-filled syringes in a carton <p>Packaging images available at Label: BEYFORTUS- nirsevimab injection (DailyMed)</p>	<p>Packaged as one or ten single-dose prefilled type I glass syringe(s) with Luer Lock and plunger stopper. The prefilled syringe is not made with natural rubber latex.</p> <p>Packaging images available at Label: ENFLONIA- clesrovimab injection, solution (DailyMed)</p>

Vaccine Fact Sheet: RSV

Topic	Nirsevimab (Beyfortus™)	Clesrovimab (Enflonsia™)
Dosage	<p>Age <8 months:</p> <ul style="list-style-type: none"> Weight <5 kg: 50 mg dose (purple plunger rod) Weight ≥5 kg: 100 mg dose (light blue plunger rod) <p>Age 8-19 months:</p> <ul style="list-style-type: none"> 200 mg dose (2 separate 100 mg injections, at the same time at different sites) 	<p>Age < 8 months: 105mg/0.7mL single-dose prefilled syringe regardless of weight</p>
Shipping	Nirsevimab ships similarly to other pediatric routine vaccines	Clesrovimab ships similarly to other pediatric routine vaccines
Storage	<p>Routine Storage: In a refrigerator at 2°C– 8°C; DO NOT FREEZE.</p> <p>Short-term storage: Room temperature (20°C – 25°C) for 8 hours if protected from light</p>	<p>Routine Storage: In a refrigerator at 2°C– 8°C; DO NOT FREEZE. DO NOT SHAKE.</p> <p>Short-term storage: Room temperature (20°C – 25°C) for maximum 48 hours or discarded</p>
Use-by Limit	Nirsevimab has a shelf life of about 18 months. Once removed from the refrigerator, it must be used within 8 hours or discarded.	Clesrovimab has a shelf life of about 30 months. Once removed from the refrigerator, it must be used within 48 hours or discarded.
Expiration Date	See packaging for expiration info. Nirsevimab can be returned after expiration, similar to other Sanofi vaccine products. See AAP RSV Ordering Info .	See packaging for expiration info.
Recommendations	CDC's MMWR (2023)	CDC's MMWR (2025)
VIS	Immunization Information Statement	Immunization Information Statement Patient Information Sheet (PDF)
Program Letter	VFC Letter (PDF)	VFC Letter (PDF)
Billing Codes	NDC Code(s): 49281-574-15, 49281-574-88, 49281-575-00, 49281-575-15	NDC Code(s): 00006-5073-01, 00006-5073-02, 00006-5073-99
Comments	Licensed in 2023	Licensed in 2025

Refer to [Vaccine Fact Sheets](#) (EZIZ.org/Resources/VaccineFactSheets).